Hematological Malignancies

Overall PFS For Treatment Groups 7-year overall PFS 23% in control arm compared with 47% in 90 Y-ibritumomab arm HR = 2.09 (95% CI: 1.63 – 2.67); P < 0.001

100

75

90 Y-ibritumomab: n = 207 Median PFS: 49.3 mo

50

25

Control: n = 202 Median PFS: 12.6 mo

N

F

Cumulative Percentage 90 Y-ibritumomab Control

207 202

110 149

0

0

21

42

63

84

PFS From Time of Randomization (months)

At risk:

25 14

90 Y-ibritumomab Control

207 202

143 86

102 63

89 48